This study substantiates the key contribution of inflammatory markers (i.e., TNF-α) in combination with plasma Aβ1−42 levels and increased proNGF levels to better predict the worsening of “latent” AD pathology with the consequential cognitive decline in Down syndrome patients (115). This evidence concerns the gene TNF and Down syndrome.